Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

In patients with cancer, one of the main mechanism of resistance to antimetabolite drugs is related to higher levels of thymidylate synthase (TS) activity.

[1]  J. Peters,et al.  Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence , 2000, Journal of Gastrointestinal Surgery.

[2]  G. Scagliotti,et al.  Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. , 2006, American journal of clinical pathology.

[3]  Y. Ozeki,et al.  Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung , 2006, Cancer.

[4]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[5]  K. Hayashi,et al.  Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer , 2006, Clinical Cancer Research.

[6]  Maria Paola Costi,et al.  Thymidylate synthase structure, function and implication in drug discovery. , 2005, Current medicinal chemistry.

[7]  H. Wada,et al.  Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Scagliotti,et al.  Cathepsin K Is Selectively Expressed in the Stroma of Lung Adenocarcinoma but Not in Bronchioloalveolar Carcinoma , 2005 .

[9]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Tsubota,et al.  A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[12]  S. Miyoshi,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. , 2004, Lung cancer.

[13]  S. Kudoh,et al.  Uracil/Tegafur Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer , 2004, Clinical Cancer Research.

[14]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[16]  V. Hans,et al.  Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. , 2004, Oncology reports.

[17]  M. Fukushima,et al.  Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). , 2004, Lung cancer.

[18]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Adjei.  Pemetrexed in the treatment of selected solid tumors. , 2002, Seminars in oncology.

[21]  L. Crinò,et al.  Pemetrexed combination therapy in the treatment of non-small cell lung cancer. , 2002, Seminars in oncology.

[22]  D. Sargent,et al.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Fukushima,et al.  Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. , 2002, Lung cancer.

[24]  K. Yamasawa,et al.  Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives , 2002, Anti-cancer drugs.

[25]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  P. Norman.  Pemetrexed disodium (Eli Lilly). , 2001, Current opinion in investigational drugs.

[29]  N. Saijo,et al.  Novel combination chemotherapy in the treatment of non-small cell lung cancer , 2000, Expert opinion on pharmacotherapy.

[30]  B. Trock,et al.  Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .

[31]  R. Nishimura,et al.  Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. , 1999, Anticancer research.

[32]  B. Trock,et al.  Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  S. Groshen,et al.  p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  G. Wampler,et al.  A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[36]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.